Hospira wins U.K. patent suit

• London's High Court rules Roche's (OTCQX:RHHBY -0.7%) 115 and 455 Herceptin patents are invalid paving the way for Hospira (HSP -3.5%) to market a biosimilar version in Britain.
• Hospira wants to sell its offering of trastuzumab after Herceptin's core patent expires on July 28.
• Although Britain comprises a small part of Herceptin's $6.9B sales, Roche is carefully assessing its options in light of a possible domino effect in other European countries.